ISO 10993-1:2025: The Lifecycle Approach Changes Everything

What Changed in ISO 10993-1:2025?

The core change is the lifecycle approach. Biological evaluation is no longer framed only around the finished device at a single point in time. The file now needs to show how biological safety is managed across material sourcing, manufacturing, sterilization, packaging, storage, transport where relevant, and clinical use.

Biological Evaluation Across the Full Device Lifecycle

That lifecycle shift has practical consequences for documentation. It means the evaluation needs to consider:

• Raw material variability: whether upstream material differences can affect biological risk.
• Manufacturing and process state: whether cleaning, assembly, coatings, or other processing steps change the final biological profile.
• Sterilization and packaging: whether sterilization residuals, package interaction, or storage conditions affect chemical or biological safety.
• Change control: whether supplier, formulation, design, or process changes should trigger re-evaluation.

Benefit-Risk Determination Now Has to Be Explicit

The 2025 revision expects benefit-risk language to be clearer and more device specific. Generic statements such as "the benefits outweigh the risks" are weak. Reviewers now expect the BER to show how residual biological risk was considered in the context of the device's intended use and clinical benefit.

Test Waivers Are Encouraged, But the Bar Is Higher

The standard is more comfortable with using existing evidence instead of default testing. That is a good shift, but it only works when the waiver rationale is clearly tied to the device materials, contact type, duration, and evidence quality. Weak waiver language stands out faster under the newer framing.

Chemical Characterization Is More Central

ISO 10993-18 chemical characterization and ISO 10993-17 toxicological risk assessment now play a more central role in endpoint strategy and waiver logic. For many devices, chemistry is no longer a supporting appendix. It is part of the main biological safety argument.

What This Means for Existing BEP and BER Files

If the file was built around the 2018 version, it may still be scientifically useful but structurally outdated. Common questions to ask include:

• Does the BEP visibly cover the full lifecycle rather than only finished-device testing?
• Is the benefit-risk conclusion explicit and device specific?
• Are waived endpoints defended with evidence that actually represents the current device?
• Is chemistry or TRA integrated into endpoint selection and conclusions where appropriate?
• Is the biological evaluation clearly linked to the ISO 14971 risk-management file?

Why Legacy Files Often Trigger Review Friction

Older files often fail not because all the science is wrong, but because the story is incomplete. Typical gaps include no lifecycle framing, generic benefit-risk wording, outdated waiver rationale, and poor alignment between BEP, BER, chemistry inputs, and risk management.

Practical Update Path

For most teams, the right move is not to rewrite everything blindly. It is to perform a focused gap analysis, identify which parts of the file are still defensible, and update the sections that are structurally out of step with 2025 expectations.